- Home
- CHAC vs NGNE Comparison
CHAC vs NGNE Comparison
Compare CHAC & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHAC
- NGNE
- Stock Information
- Founded
- CHAC 2025
- NGNE 2003
- Country
- CHAC United States
- NGNE United States
- Employees
- CHAC N/A
- NGNE N/A
- Industry
- CHAC
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- CHAC
- NGNE Health Care
- Exchange
- CHAC NYSE
- NGNE Nasdaq
- Market Cap
- CHAC 300.0M
- NGNE 325.3M
- IPO Year
- CHAC 2025
- NGNE N/A
- Fundamental
- Price
- CHAC $10.10
- NGNE $21.78
- Analyst Decision
- CHAC
- NGNE Strong Buy
- Analyst Count
- CHAC 0
- NGNE 7
- Target Price
- CHAC N/A
- NGNE $41.86
- AVG Volume (30 Days)
- CHAC 457.0
- NGNE 129.7K
- Earning Date
- CHAC 01-01-0001
- NGNE 08-12-2025
- Dividend Yield
- CHAC N/A
- NGNE N/A
- EPS Growth
- CHAC N/A
- NGNE N/A
- EPS
- CHAC N/A
- NGNE N/A
- Revenue
- CHAC N/A
- NGNE $925,000.00
- Revenue This Year
- CHAC N/A
- NGNE N/A
- Revenue Next Year
- CHAC N/A
- NGNE N/A
- P/E Ratio
- CHAC N/A
- NGNE N/A
- Revenue Growth
- CHAC N/A
- NGNE N/A
- 52 Week Low
- CHAC $9.98
- NGNE $6.88
- 52 Week High
- CHAC $11.28
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- CHAC N/A
- NGNE 54.39
- Support Level
- CHAC N/A
- NGNE $21.16
- Resistance Level
- CHAC N/A
- NGNE $23.80
- Average True Range (ATR)
- CHAC 0.00
- NGNE 1.52
- MACD
- CHAC 0.00
- NGNE -0.18
- Stochastic Oscillator
- CHAC 0.00
- NGNE 33.59
About CHAC CRANE HBR ACQUISITION CORP
Crane Harbor Acquisition Corp is a blank check company.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.